{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:36:25Z","timestamp":1790876185434,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070551"],"award-info":[{"award-number":["82070551"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Clinical Research Center for Digestive Diseases supporting technology project","award":["2015BAI13B07"],"award-info":[{"award-number":["2015BAI13B07"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s10620-024-08460-3","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T08:01:55Z","timestamp":1714723315000},"page":"2540-2547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Bismuth-Containing Quadruple Therapy for Helicobacter pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days"],"prefix":"10.1007","volume":"69","author":[{"given":"Yu-Ming","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Xue","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hui","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Lan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-yan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Zhou","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Juan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Shen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-ping","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Li","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,3]]},"reference":[{"key":"8460_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/jgh.15751","volume":"37","author":"S Ren","year":"2022","unstructured":"Ren S, Cai P, Liu Y et al. Prevalence of Helicobacter pylori infection in China: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2022;37:464\u2013470. https:\/\/doi.org\/10.1111\/jgh.15751.","journal-title":"J Gastroenterol Hepatol."},{"key":"8460_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/cm9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia C, Dong X, Li H et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135:584\u2013590. https:\/\/doi.org\/10.1097\/cm9.0000000000002108.","journal-title":"Chin Med J (Engl)."},{"key":"8460_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12475","volume":"23","author":"WZ Liu","year":"2018","unstructured":"Liu WZ, Xie Y, Lu H et al. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter. 2018;23:e12475. https:\/\/doi.org\/10.1111\/hel.12475.","journal-title":"Helicobacter."},{"key":"8460_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","volume":"66","author":"P Malfertheiner","year":"2017","unstructured":"Malfertheiner P, Megraud F, O\u2019Morain CA et al. Management of Helicobacter pylori infection-the Maastricht V\/Florence Consensus Report. Gut. 2017;66:6\u201330. https:\/\/doi.org\/10.1136\/gutjnl-2016-312288.","journal-title":"Gut."},{"key":"8460_CR5","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1136\/gutjnl-2020-322368","volume":"69","author":"JM Liou","year":"2020","unstructured":"Liou JM, Malfertheiner P, Lee YC et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020;69:2093\u20132112. https:\/\/doi.org\/10.1136\/gutjnl-2020-322368.","journal-title":"Gut."},{"key":"8460_CR6","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1097\/CM9.0000000000002546","volume":"135","author":"L Zhou","year":"2022","unstructured":"Zhou L, Lu H, Song Z et al. 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment. Chin Med J (Engl). 2022;135:2899\u20132910. https:\/\/doi.org\/10.1097\/CM9.0000000000002546.","journal-title":"Chin Med J (Engl)."},{"key":"8460_CR7","doi-asserted-by":"crossref","unstructured":"Kato MA-O, Ota H, Okuda MA-O, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition. Helicobacter. 2019.","DOI":"10.1111\/hel.12597"},{"key":"8460_CR8","doi-asserted-by":"publisher","first-page":"168","DOI":"10.5009\/gnl20288","volume":"15","author":"HK Jung","year":"2021","unstructured":"Jung HK, Kang SJ, Lee YC et al. Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020. Gut Liver. 2021;15:168\u2013195. https:\/\/doi.org\/10.5009\/gnl20288.","journal-title":"Gut Liver."},{"key":"8460_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-022-00953-7","author":"YM Ding","year":"2022","unstructured":"Ding YM, Li YY, Liu J et al. The cure rate of 10-day bismuth-containing quadruple therapy for Helicobacter pylori eradication is equivalent to 14-day: a systematic review and meta-analysis. Clin Exp Med. 2022. https:\/\/doi.org\/10.1007\/s10238-022-00953-7.","journal-title":"Clin Exp Med."},{"key":"8460_CR10","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1111\/jgh.15468","volume":"36","author":"C Qiao","year":"2021","unstructured":"Qiao C, Li Y, Liu J et al. Clarithromycin versus furazolidone for na\u00efve Helicobacter pylori infected patients in a high clarithromycin resistance area. J Gastroenterol Hepatol. 2021;36:2383\u20132388. https:\/\/doi.org\/10.1111\/jgh.15468.","journal-title":"J Gastroenterol Hepatol."},{"key":"8460_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/sim.1425","volume":"22","author":"RB D'Agostino Sr","year":"2003","unstructured":"D\u2019Agostino RB Sr, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics. Stat Med. 2003;22:169\u2013186. https:\/\/doi.org\/10.1002\/sim.1425.","journal-title":"Stat Med."},{"issue":"780","key":"8460_CR12","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.cmi.2017.11.010","volume":"24","author":"DS Liu","year":"2018","unstructured":"Liu DS, Wang YH, Zeng ZR et al. Primary antibiotic resistance of Helicobacter pylori in Chinese patients: a multiregion prospective 7-year study. Clin Microbiol Infect. 2018;24:e5\u2013e8. https:\/\/doi.org\/10.1016\/j.cmi.2017.11.010.","journal-title":"Clin Microbiol Infect."},{"key":"8460_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12930","volume":"27","author":"Z Han","year":"2022","unstructured":"Han Z, Li Y, Kong Q et al. Efficacy of bismuth for antibiotic-resistant Helicobacter pylori strains eradication: A systematic review and meta-analysis. Helicobacter. 2022;27:e12930. https:\/\/doi.org\/10.1111\/hel.12930.","journal-title":"Helicobacter."},{"key":"8460_CR14","doi-asserted-by":"publisher","unstructured":"Qian HS, Li WJ, Dang YN, et al. Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy. Am J Gastroenterol. 2023;118:627\u201334. https:\/\/doi.org\/10.14309\/ajg.0000000000002086.","DOI":"10.14309\/ajg.0000000000002086"},{"key":"8460_CR15","doi-asserted-by":"publisher","unstructured":"Graham DY. It Is Time for a Paradigm Shift in Design, Execution, and Publishing of Comparative Helicobacter pylori Treatment Trials. Am J Gastroenterol. 2023;118:1154\u20136. https:\/\/doi.org\/10.14309\/ajg.0000000000002298.","DOI":"10.14309\/ajg.0000000000002298"},{"key":"8460_CR16","doi-asserted-by":"publisher","first-page":"5519","DOI":"10.2147\/IDR.S383444","volume":"15","author":"H Xu","year":"2022","unstructured":"Xu H, Yun J, Li R et al. Antibiotics Resistance Prevalence of Helicobacter pylori Strains in Northwest China. Infect Drug Resist. 2022;15:5519\u20135528. https:\/\/doi.org\/10.2147\/IDR.S383444.","journal-title":"Infect Drug Resist."},{"key":"8460_CR17","doi-asserted-by":"publisher","first-page":"17754","DOI":"10.1038\/s41598-022-21661-y","volume":"12","author":"X Shu","year":"2022","unstructured":"Shu X, Ye D, Hu C et al. Alarming antibiotics resistance of Helicobacter pylori from children in Southeast China over 6 years. Sci Rep. 2022;12:17754. https:\/\/doi.org\/10.1038\/s41598-022-21661-y.","journal-title":"Sci Rep."},{"key":"8460_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12912","volume":"27","author":"Q Kong","year":"2022","unstructured":"Kong Q, Li Y, Li R et al. Low compliance to post-screening recommendations in a family-based Helicobacter pylori screening and treatment program: A prospective cohort study. Helicobacter. 2022;27:e12912. https:\/\/doi.org\/10.1111\/hel.12912.","journal-title":"Helicobacter."},{"key":"8460_CR19","doi-asserted-by":"publisher","unstructured":"Tsuda M, Asaka M, Kato M, et al. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter. 2017;22. https:\/\/doi.org\/10.1111\/hel.12415.","DOI":"10.1111\/hel.12415"},{"key":"8460_CR20","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1159\/000500819","volume":"101","author":"H Deguchi","year":"2020","unstructured":"Deguchi H, Uda A, Murakami K. Current Status of Helicobacter pylori Diagnosis and Eradication Therapy in Japan Using a Nationwide Database. Digestion. 2020;101:441\u2013449. https:\/\/doi.org\/10.1159\/000500819.","journal-title":"Digestion."},{"key":"8460_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40880-019-0372-x","volume":"39","author":"K Gao","year":"2019","unstructured":"Gao K, Wu J. National trend of gastric cancer mortality in China (2003\u20132015): a population-based study. Cancer Commun (Lond). 2019;39:24. https:\/\/doi.org\/10.1186\/s40880-019-0372-x.","journal-title":"Cancer Commun (Lond)."},{"key":"8460_CR22","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1007\/s10620-019-05910-1","volume":"65","author":"Y Han","year":"2020","unstructured":"Han Y, Yan T, Ma H et al. Cost-Effectiveness Analysis of Helicobacter pylori Eradication Therapy for Prevention of Gastric Cancer: A Markov Model. Dig Dis Sci. 2020;65:1679\u20131688. https:\/\/doi.org\/10.1007\/s10620-019-05910-1.","journal-title":"Dig Dis Sci."},{"key":"8460_CR23","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1046\/j.1365-2036.2002.01204.x","volume":"16","author":"J Mason","year":"2002","unstructured":"Mason J, Axon AT, Forman D et al. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. Aliment Pharmacol Ther. 2002;16:559\u2013568. https:\/\/doi.org\/10.1046\/j.1365-2036.2002.01204.x.","journal-title":"Aliment Pharmacol Ther."},{"key":"8460_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1136\/gutjnl-2020-322200","volume":"70","author":"TH Chiang","year":"2021","unstructured":"Chiang TH, Chang WJ, Chen SL et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. Gut. 2021;70:243\u2013250. https:\/\/doi.org\/10.1136\/gutjnl-2020-322200.","journal-title":"Gut."},{"key":"8460_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/ncpgasthep1138","volume":"5","author":"DY Graham","year":"2008","unstructured":"Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol. 2008;5:321\u2013331. https:\/\/doi.org\/10.1038\/ncpgasthep1138.","journal-title":"Nat Clin Pract Gastroenterol Hepatol."},{"key":"8460_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1124\/jpet.110.170274","volume":"335","author":"Y Hori","year":"2010","unstructured":"Hori Y, Imanishi A, Matsukawa J et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010;335:231\u2013238. https:\/\/doi.org\/10.1124\/jpet.110.170274.","journal-title":"J Pharmacol Exp Ther."},{"key":"8460_CR27","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/apt.13121","volume":"41","author":"H Jenkins","year":"2015","unstructured":"Jenkins H, Sakurai Y, Nishimura A et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41:636\u2013648. https:\/\/doi.org\/10.1111\/apt.13121.","journal-title":"Aliment Pharmacol Ther."},{"key":"8460_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.18","volume":"6","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Nishimura A, Kennedy G et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese\/non-Japanese Subjects. Clin Transl Gastroenterol. 2015;6:e94. https:\/\/doi.org\/10.1038\/ctg.2015.18.","journal-title":"Clin Transl Gastroenterol."},{"key":"8460_CR29","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","volume":"163","author":"WD Chey","year":"2022","unstructured":"Chey WD, M\u00e9graud F, Laine L, L\u00f3pez LJ, Hunt BJ, Howden CW. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology. 2022;163:608\u2013619. https:\/\/doi.org\/10.1053\/j.gastro.2022.05.055.","journal-title":"Gastroenterology."},{"key":"8460_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1053\/j.gastro.2021.04.012","volume":"161","author":"T Rokkas","year":"2021","unstructured":"Rokkas T, Gisbert JP, Malfertheiner P et al. Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. Gastroenterology. 2021;161:495-507.e4. https:\/\/doi.org\/10.1053\/j.gastro.2021.04.012.","journal-title":"Gastroenterology."},{"key":"8460_CR31","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1111\/jgh.15252","volume":"36","author":"DY Graham","year":"2021","unstructured":"Graham DY, Lu H, Shiotani A. Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance. J Gastroenterol Hepatol. 2021;36:1159\u20131163. https:\/\/doi.org\/10.1111\/jgh.15252.","journal-title":"J Gastroenterol Hepatol."},{"key":"8460_CR32","doi-asserted-by":"publisher","first-page":"175628482096873","DOI":"10.1177\/1756284820968736","volume":"13","author":"JP Gisbert","year":"2020","unstructured":"Gisbert JP. Empirical or susceptibility-guided treatment for Helicobacter pylori infection? A comprehensive review. Therap Adv Gastroenterol. 2020;13:1756284820968736. https:\/\/doi.org\/10.1177\/1756284820968736.","journal-title":"A comprehensive review. Therap Adv Gastroenterol."},{"key":"8460_CR33","doi-asserted-by":"publisher","unstructured":"Li P, Jin J, Chen Y, Ma J, Du Q, Han Y. Susceptibility-guided vs. empirical 10-day quadruple treatment for Helicobacter pylori-infected patients: A prospective clinical trial of first-line therapy. Front Microbiol. 2022;13:973975. https:\/\/doi.org\/10.3389\/fmicb.2022.973975.","DOI":"10.3389\/fmicb.2022.973975"},{"key":"8460_CR34","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1038\/ajg.2017.195","volume":"11","author":"PI Hsu","year":"2017","unstructured":"Hsu PI, Tsai FW, Kao SS et al. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial. Am J Gastroenterol. 2017;11:1374\u20131381. https:\/\/doi.org\/10.1038\/ajg.2017.195.","journal-title":"Am J Gastroenterol."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08460-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-024-08460-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08460-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T22:05:08Z","timestamp":1721340308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-024-08460-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["8460"],"URL":"https:\/\/doi.org\/10.1007\/s10620-024-08460-3","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,3]]},"assertion":[{"value":"5 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the Helsinki Declaration and its later amendments. The study was approved by the Medical Ethics Committee of Qilu Hospital of Shandong University (No. 2021028).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}